Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00259818 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by Erimos Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00259818 is a Phase 1 study that has completed, run by Erimos Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT00259818, a Phase 1 study, has completed, sponsored by Erimos Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase I, dose escalation study of EM-1421 administered by intravenous infusion (IV) for five consecutive days every 28 days to patients with solid tumors refractory to current therapies. There have been no previous human studies of intravenous (into one's vein) EM-1421 treatment; however, lab research (research in test tubes and/or animals) suggests that EM-1421 has shown some activity against tumors in animals. This activity in animal models suggests that EM-1421 may be a useful chemotherapy for human cancer. The primary objective of this study is to determine the safety and maximum tolerated dose of EM-1421 given by intravenous infusion. The efficacy of the treatment will also be measured.
Interventions
- DRUG EM-1421
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00259818
The ClinicalTrials.gov registry entry for NCT00259818 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Erimos Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EM-1421 is the first listed.
NCT00259818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00259818 about?
NCT00259818 is a clinical study titled "Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors". This is a Phase I, dose escalation study of EM-1421 administered by intravenous infusion (IV) for five consecutive days every 28 days to patients with solid tumors refractory to current therapies. There have been no previous human studies of intravenous (into one's vein) EM-1421 treatment; however, ...
What is the current status of trial NCT00259818?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2005-12. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00259818?
The interventions under investigation include: EM-1421 (DRUG).
Who is sponsoring clinical trial NCT00259818?
This trial is sponsored by Erimos Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.